Why Is AGIO Stock Falling Today?
Agios Pharmaceuticals (AGIO) shares dropped over 4% after the company announced it would stop developing its sickle cell disease therapy, Tebapivat, due to disappointing Phase 2 trial results. The drug's profile was not sufficiently differentiated from existing treatments, leading Agios to pivot its focus to Mitapivat, for which a key regulatory decision is expected by November 1, 2026. Despite the setback, retail sentiment for AGIO has shifted to 'neutral' from 'bearish' with high message volumes, and the stock has gained over 39% year-to-date.
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
Agios Pharmaceuticals is heavily relying on its lead therapy, mitapivat, for commercial growth as it expands into multiple blood disorders, including pyruvate kinase deficiency and thalassemia, and seeks approval for sickle cell disease. Despite strong early commercial performance for Pyrukynd and Aqvesme, the company faces significant competition from other pharmaceutical giants like Novo Nordisk and Bristol Myers Squibb in its target markets. The discontinuation of a next-generation growth driver, tebapivat, further underscores mitapivat's critical role in Agios's near-to-medium-term success.
How (AGIO) Movements Inform Risk Allocation Models
This article analyzes Agios Pharmaceuticals Inc. (NASDAQ: AGIO) using AI models to provide trading strategies and risk allocation insights. It identifies weak near-term sentiment but highlights an exceptional 78.6:1 risk-reward setup targeting a 22.2% gain. The report offers specific position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis for various holding periods.
Is Agios Pharmaceuticals (AGIO) Undervalued On Its PYRUKYND Expansion Story?
Agios Pharmaceuticals (AGIO) is drawing attention due to its share price movements and focus on rare diseases, particularly with its drug PYRUKYND. The stock is currently seen as undervalued by some metrics, trading at $34.19 against a fair value of $44.00, especially with the upcoming potential FDA approval for thalassemia. However, other valuation metrics like the P/S ratio suggest it might be expensive compared to industry peers, indicating mixed signals for investors.
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
Agios Pharmaceuticals (AGIO) has acquired exclusive global rights to cevidoplenib, a late-stage SYK inhibitor, from Oscotec for immune thrombocytopenia (ITP). This deal expands Agios's rare hematology portfolio, adding a potential treatment with significant sales potential, despite a recent share dip due to concerns over another drug's discontinuation. Agios plans to advance cevidoplenib into a Phase III study for ITP in early 2028.
AGIOS PHARMACEUTICALS, INC. : BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $50 FROM $46
BofA Global Research has raised its price objective for Agios Pharmaceuticals, Inc. (AGIO) to $50 from $46. This financial update indicates a positive outlook from the research firm regarding the company's stock performance. The article also provides a disclaimer stating that the content is solely the author's opinion and not investment advice.
AGIO Maintained by B of A Securities -- Price Target Raised to $50
B of A Securities has maintained a "Buy" rating for Agios Pharmaceuticals (AGIO) and increased its price target from $46.00 to $50.00. While GuruFocus indicates AGIO is significantly undervalued based on its GF Value, the company faces profitability challenges and has a low GF Score of 46/100, alongside recent insider selling activity. Investors are advised to exercise caution due to these mixed signals.
(AGIO) Price Dynamics and Execution-Aware Positioning
This article provides an AI-generated analysis of Agios Pharmaceuticals Inc. (NASDAQ: AGIO), highlighting strong near and mid-term sentiment but a weak long-term outlook. It details three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths and key support and resistance levels for AGIO.
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Agios Pharmaceuticals (AGIO) is projected to report increased earnings and higher revenues for Q2 2026, with an expected loss of $1.86 per share and revenues of $22.68 million. The company has a positive Zacks Earnings ESP of +12.67% and a Zacks Rank of #3, indicating a high probability of beating consensus EPS estimates. Agios has a history of outperforming EPS estimates in three of the last four quarters.
Bank of America Corp DE Sells 31,441 Shares of Agios Pharmaceuticals, Inc. $AGIO
Bank of America Corp DE reduced its stake in Agios Pharmaceuticals (NASDAQ:AGIO) by 5.8% in Q1 2026, selling 31,441 shares and retaining 507,900 shares valued at $17.2 million. The biopharmaceutical company reported a quarterly loss of $1.69 per share, slightly worse than expectations, but revenue of $44.75 million surpassed estimates. Analyst sentiment is mixed, with an average "Hold" rating and a price target of $41.25 for AGIO.
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
The article discusses Agios Pharmaceuticals' cash burn rate, expressing a lack of significant concern despite the company operating at a loss. It likely details the company's financial position, how its cash reserves compare to its burn, and the market's perception of its financial health.
Agios Pharmaceuticals (AGIO) Could Be 24% Undervalued On PYRUKYND Growth Hopes
Agios Pharmaceuticals (AGIO) is considered 23.6% undervalued, trading at $33.63 against a narrative fair value of $44.00, driven by the anticipated FDA approval and commercial launch of PYRUKYND for thalassemia. While recent share price performance shows strong short-term gains, the stock's P/S ratio of 20.4x is significantly higher than the industry average, indicating considerable execution risk. Investors are advised to review underlying data and risks associated with PYRUKYND's execution and ongoing spending.
Agios Pharmaceuticals (AGIO) Could Be 24% Undervalued On PYRUKYND Growth Hopes
Agios Pharmaceuticals (AGIO) is drawing investor attention due to its rare disease portfolio and the potential undervaluation of its stock. Despite mixed past returns, the company's shares are considered undervalued by some analyses, particularly with the anticipated FDA approval and commercial launch of PYRUKYND for thalassemia in the U.S. However, a high P/S ratio indicates significant execution risk, suggesting investors need to weigh growth opportunities against ongoing spending and safety concerns.
612,850 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by SCS Capital Management LLC
SCS Capital Management LLC acquired 612,850 shares of Agios Pharmaceuticals (NASDAQ:AGIO) during the second quarter, valued at approximately $22.7 million. The biopharmaceutical company reported a quarterly loss per share of $1.69, missing estimates, but exceeded revenue expectations with $44.75 million. Analyst sentiment for AGIO is mixed, with a consensus "Hold" rating and an average price target of $41.25.
Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO
Assenagon Asset Management S.A. significantly increased its stake in Agios Pharmaceuticals, Inc. by 54.8% during the second quarter, bringing its total holdings to 103,955 shares valued at $3.86 million. This increase occurred despite Agios Pharmaceuticals reporting a slightly wider-than-expected quarterly loss of $1.69 per share, though its revenue of $44.75 million surpassed analyst forecasts. The biopharmaceutical company currently holds a consensus "Hold" rating from analysts with an average price target of $41.25.
Agios Pharmaceuticals faces investigation after halting sickle cell drug development, stock drops 6.74%.
Agios Pharmaceuticals is under investigation by Pomerantz LLP for potential securities fraud after its stock fell 6.74%. This drop occurred following the company's announcement to cease development of tebapivat, a sickle cell disease drug, due to disappointing Phase 2 trial results. Investors affected by this situation are encouraged to contact Pomerantz LLP for potential class action involvement.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Agios Pharmaceuticals, Inc. (AGIO) following a significant stock drop. The investigation stems from Agios's announcement that its Phase 2 trial for tebapivat in sickle cell disease did not meet the necessary differentiation for continued development, causing a 6.74% share price decrease. The law firm is encouraging investors who purchased Agios securities to learn more about the investigation and potentially assist with claims.
Q4 2025 Agios Pharmaceuticals Inc Earnings Call Transcript
Agios Pharmaceuticals reported strong Q4 and full-year 2025 results, driven by the successful launch of AQVESME for thalassemia and robust PYRUKYND revenue. The company ended 2025 with $1.2 billion in cash, has a clear path to profitability, and is advancing its pipeline, including a phase 2 sickle cell disease trial. However, challenges include delayed revenue recognition for AQVESME, anticipated sequential decline in ex-US revenues, increased R&D expenses, and regulatory hurdles for mitapivat in sickle cell disease.
Agios Pharmaceuticals, Inc. (AGIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Agios Pharmaceuticals, Inc. (AGIO) on behalf of investors. This investigation follows a significant stock price drop on July 21, 2026, after Agios announced that its Phase 2 trial of tebapivat for sickle cell disease did not show sufficient differentiation to continue development. The firm is encouraging investors affected by this news to contact them for more information.
Sei Investments Co. Acquires 49,198 Shares of Agios Pharmaceuticals, Inc. $AGIO
Sei Investments Co. significantly increased its stake in Agios Pharmaceuticals (NASDAQ:AGIO) by 342.8% in the first quarter, now holding 63,550 shares valued at $2.15 million. This comes as Agios Pharmaceuticals reported a quarterly loss but exceeded revenue estimates. Analyst sentiment on AGIO is mixed but generally positive, with a consensus "Hold" rating and an average price target of $41.25.
Agios Pharmaceuticals (AGIO) In Focus On Earnings As Undervalued Narrative Holds
Agios Pharmaceuticals (AGIO) reported Q2 2026 results with revenue of US$44.75 million and a net loss of US$100.7 million. Despite short-term stock momentum, the company is considered undervalued at $32.27 against a fair value of $44.00, largely due to the potential of its key asset, PYRUKYND. However, the stock appears expensive on a sales multiple basis, trading at 19.6x P/S compared to an industry average of 11.6x, highlighting valuation risk if sentiment shifts.
Agios Pharmaceuticals (AGIO) In Focus On Earnings As Undervalued Narrative Holds
Agios Pharmaceuticals (AGIO) is currently in focus after reporting its Q2 2026 results, showing US$44.75 million in revenue and a US$100.7 million net loss. Despite mixed long-term returns, recent performance has improved, leading to a narrative that the stock is 26.7% undervalued with a fair value estimate of $44.00, largely driven by the potential of its key asset, PYRUKYND. However, the company also faces concentration risk and appears expensive on sales multiples compared to industry averages.
Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Raised to $34.00 at JPMorgan Chase & Co.
JPMorgan Chase & Co. has increased its price target for Agios Pharmaceuticals (NASDAQ:AGIO) from $31.00 to $34.00, maintaining a "neutral" rating. This adjustment suggests a potential upside of 7.19% from the stock's previous close. Despite missing quarterly EPS estimates, the company's revenue exceeded expectations, and analyst sentiment remains mixed with an average "Hold" rating and a consensus price target of $41.25.
How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals (AGIO) Investors
Agios Pharmaceuticals reported a significant revenue increase in Q2 2026, reaching US$44.75 million, up from US$12.46 million a year prior, while net losses slightly narrowed. This growth is driven by the traction of recent approvals and launches, with the FDA's Priority Review of PYRUKYND for sickle cell disease being a key near-term catalyst. Despite increased sales, substantial losses continue, underscoring the company's need to successfully expand its rare-disease franchise to justify current spending and improve its financial outlook.
Agios Pharmaceuticals, Inc. (AGIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) after the company announced that its Phase 2 trial for tebapivat in sickle cell disease did not meet the required differentiation for continued development. This news led to a 6.74% drop in Agios's stock price. The law firm is encouraging affected shareholders to contact them to learn more about the investigation into potential claims.
Agios Pharmaceuticals (AGIO) CMO sells 30,000 shares in plan trade
Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, sold 30,000 shares of common stock on August 4, 2026, at a weighted average price of $30.48 per share, ranging from $30.25 to $30.88. This transaction was executed under a Rule 10b5-1 trading plan. After the sale, Gheuens directly holds 54,645 shares of the company's common stock.
How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals (AGIO) Investors
Agios Pharmaceuticals reported a significant revenue increase in Q2 2026 to US$44.75 million, up from US$12.46 million a year prior, though it continues to experience net losses, albeit slightly narrowed. The company's investment narrative heavily relies on the success of its drug PYRUKYND, especially with the upcoming FDA Priority Review for sickle cell disease, which could expand its market and help justify current spending despite ongoing losses. Analysts project substantial revenue growth for Agios by 2029, suggesting a potential 39% upside to its current price.
How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals (AGIO) Investors
Agios Pharmaceuticals (AGIO) reported a significant revenue increase in Q2 2026, reaching US$44.75 million, with a reduced net loss, suggesting that sales growth is starting to alleviate their financial losses. The company's investment narrative centers on PYRUKYND's potential to anchor a broader rare-disease franchise, especially with the FDA's Priority Review for sickle cell disease. Despite increased revenue, substantial losses persist, making cash burn and execution on new indications critical factors for investors.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Agios Pharmaceuticals, Inc. (AGIO) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agios Pharmaceuticals, Inc. (AGIO) after the company announced on July 21, 2026, that its Phase 2 trial for tebapivat in sickle cell disease did not meet expectations, leading to a stock price drop of 6.74%. The law firm encourages investors who purchased Agios securities to contact them to assist with the investigation, which is conducted on a contingency fee basis.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Pomerantz LLP is investigating potential claims on behalf of investors of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) following a significant stock price drop. This investigation comes after Agios announced that its Phase 2 trial for tebapivat in sickle cell disease did not meet the required level of differentiation for continued development, causing a 6.74% decline in its stock on July 21, 2026. The law firm is examining whether the company's officers or directors engaged in securities fraud or other unlawful business practices.
AGIO (NASDAQ: AGIO) insider Sarah Gheuens files to sell 30,000 shares
AGIOS PHARMACEUTICALS, INC. (NASDAQ: AGIO) insider Sarah Gheuens has filed a Form 144 to sell up to 30,000 shares of common stock through Morgan Stanley Smith Barney LLC on August 4, 2026. The shares are related to previous equity awards, including restricted stock units and performance shares granted in 2020. The filing also notes a recent sale of 4,007 shares for $150,517.75 on July 1, 2026.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Recommendation of "Hold" by Brokerages
Agios Pharmaceuticals (NASDAQ:AGIO) has received a consensus "Hold" rating from ten brokerages, with an average 12-month price target of $40.88, surpassing its current share price of $30.02. The company's revenue increased to $44.75 million, exceeding estimates, primarily due to its mitapivat products. Despite this, Agios reported a loss of $1.69 per share, missing estimates, and remains unprofitable, though a priority review for mitapivat in sickle cell disease by the FDA could expand its market.
Agios Pharmaceuticals, Inc. (AGIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agios Pharmaceuticals, Inc. (AGIO) after the company announced that its Phase 2 trial for tebapivat in sickle cell disease did not meet the required level of differentiation, leading to a decision not to continue its development. Following this news, Agios's stock price dropped by $2.70 per share, or 6.74%. The law firm encourages affected shareholders to contact them to learn more about the investigation.
Farallon Capital (AGIO) discloses 5.9M-share, 9.9% position in Agios
Farallon Capital Management, L.L.C. and its affiliated investment funds have disclosed a beneficial ownership of 5,917,400 shares, representing 9.9% of Agios Pharmaceuticals, Inc.'s common stock. This information was reported in an amended Schedule 13G/A filing with the SEC. The filing details various Farallon entities and individuals who share voting and dispositive power over these shares, held through multiple investment partnerships.
Agios Pharmaceuticals, Inc. (AGIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) following a significant stock price drop. The investigation stems from Agios's announcement that its Phase 2 trial for tebapivat in sickle cell disease did not meet expectations, leading the company to discontinue its development. Investors who purchased Agios securities are encouraged to contact the firm to learn more about participating in the investigation.
ETFs Investing in Agios Pharmaceuticals, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Agios Pharmaceuticals, Inc. It provides detailed financial data for each ETF, including market value, weight of Agios Pharmaceuticals in the fund, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, and 3-year NAV total return. The ETFs cover a range of investment focuses, from health care and biotechnology to small-cap and extended markets.
Q3 2025 Agios Pharmaceuticals Inc Earnings Call Transcript
Agios Pharmaceuticals Inc. reported a 44% increase in net revenue for Q3 2025 and a strong balance sheet with $1.3 billion in cash and investments. The company achieved its first global regulatory approval for pyrokine in Saudi Arabia for adult thalassemia, with top-line data from the Teva Pivot trial expected early next year. Despite these positive developments, the company faces challenges such as a delayed FDA PDUFA date for pyrokine thalassemia due to a REMS program request, increased R&D expenses, and potential delays in market access and revenue realization in Europe and Saudi Arabia.
Agios Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $45.38, Implies 39% Upside
The average 12-month price target for Agios Pharmaceuticals, Inc. (AGIO) stock has been raised to $45.38 from $44 by 8 analysts, implying a potential upside of approximately 39% based on the July 30 closing price. The consensus rating among 10 analysts remains "Buy," with 7 Buys, 3 Holds, and 0 Sells. This update suggests continued analyst confidence in the company's stock performance.
Agios Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data
Agios Pharmaceuticals, Inc. (AGIO) had approximately 523 employees worldwide as of March 2026, representing a 19.3% growth since 2023. The company, headquartered in Cambridge, Massachusetts, is actively hiring despite a significant decline in job postings in 2026, and its workforce is primarily concentrated in North America. Employee sentiment is neutral but improving, and the average salary is reported at $179,948.
Agios Pharmaceuticals (AGIO) Stock Sinks As Cash Burn Clouds Mitapivat Ramp
Agios Pharmaceuticals' stock dropped 8.3% after its Q2 2026 earnings report, which showed US$44.7m in revenue but a net loss of US$100.7m, highlighting concerns about its significant cash burn. While the company is making progress with its mitapivat rare disease drug and holds a US$1b cash balance, investors are worried about the heavy concentration risk in mitapivat and the long path to profitability. The market is weighing the potential of its rare disease portfolio against ongoing financial losses and balance sheet strain.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Agios Pharmaceuticals, Inc. (AGIO) following a significant drop in stock price. This comes after Agios announced that its Phase 2 trial for tebapivat in sickle cell disease did not meet expectations, leading the company to discontinue its development. The firm is encouraging affected investors to join their investigation into potential claims.
Price to sales forward of Agios Pharmaceuticals, Inc. – NASDAQ:AGIO
This article provides a brief financial overview for Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), specifically highlighting its price-to-sales forward metric. The content primarily comes from TradingView, indicating that the information is related to financial analysis and market data.
AGIOS PHARMACEUTICALS INC : CITIGROUP RAISES TARGET PRICE TO $52 FROM $46
Citigroup has increased its target price for Agios Pharmaceuticals Inc. to $52 from $46. This information was reported by Reuters on July 31, 2026. The article reiterates this new target price multiple times.
Agios Pharmaceuticals Inc (AGIO) Risk Assessment: Volatility, Financial Risk & Investment Risk
Agios Pharmaceuticals Inc (AGIO) has a risk assessment score of 3.24, placing it 149th out of 384 in the Biotechnology & Medical Research industry. The company's stock has a beta of 0.59, indicating it is less volatile than the S&P 500. This assessment provides detailed volatility, drawdown, and return metrics, including a 240-day volatility of +93.09% and a maximum drawdown of +50.89%.
Agios Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Agios Pharmaceuticals Inc has reported its earnings results for the quarter that ended on June 30. The summary of these results is available through Reuters on TradingView. Readers can access the full article and unlimited news from various sources by using TradingView.
Agios Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AGIO) 2026-07-30
Agios Pharmaceuticals, Inc. published its Q2 2026 earnings call presentation, reporting an EPS of -$1.69, missing estimates by $0.02. However, the company's revenue of $44.75M exceeded expectations by $18.04M, showing a significant 259.25% year-over-year increase. The article highlights these key financial results from the earnings presentation.
Agios Pharmaceuticals Q2 Earnings Call Highlights
Agios Pharmaceuticals reported Q2 2026 mitapivat net revenue of $44.7 million, with a net loss of $100.7 million. The company is advancing its thalassemia launch and preparing for a potential sickle cell disease approval, maintaining approximately $1 billion in cash. Key growth drivers include product expansion and pipeline programs in rare hematology and other rare diseases.
Agios Pharmaceuticals (NASDAQ: AGIO) lifts drug revenue but remains unprofitable
Agios Pharmaceuticals reported significantly increased rare-disease drug revenue, primarily from AQVESME and PYRUKYND, for the quarter and first half of 2026, though the company remains unprofitable. While product revenue rose sharply, the company still posted net losses due to substantial investments in R&D and commercialization. Agios is advancing its pipeline with mitapivat for sickle cell disease, AG-181 for phenylketonuria, AG-236 for polycythemia vera, and has licensed cevidoplenib for immune thrombocytopenia, expecting current cash reserves to fund operations for at least twelve months.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
Pomerantz LLP is investigating potential securities fraud claims against Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) on behalf of its investors. This investigation follows a significant 6.74% drop in Agios's stock price after the company announced on July 21, 2026, that its Phase 2 trial for tebapivat in sickle cell disease did not meet the required differentiation for continued development. Investors are encouraged to contact the law firm for more information regarding the class action investigation.
Agios Pharmaceuticals Q2 Results: Revenue surges 259% YoY
Agios Pharmaceuticals reported a 259% year-over-year revenue increase in Q2 2026, reaching $44.7 million, primarily due to the successful U.S. launch of AQVESME for thalassemia. The company narrowed its net loss to $100.7 million and advanced its hematology pipeline, including securing FDA Priority Review for mitapivat in sickle cell disease and licensing cevidoplenib. However, Agios discontinued the development of tebapivat for myelodysplastic syndromes and sickle cell disease due to insufficient clinical benefit or differentiation.
